Compare Amphastar Pharmaceuticals Inc (AMPH) vs Crocs, Inc. (CROX) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Crocs (CROX) trades at $132.78, up 4.44% with bullish technical signals and consistent earnings beats. The stock shows strong momentum above key support levels, though profitability metrics declined in 2025 with negative net income margins. Recent partnerships with LEGO and Disney are driving brand innovation and digital engagement.

Outlook remains mixed with analyst consensus favoring Buy (51%) but fundamental headwinds from margin pressure. Key risks include execution on international expansion and debt management. The stock trades near analyst target of $131.75 with upside to $150 if growth initiatives succeed.